Viatris (VTRS) Research & Development (2020 - 2026)
Viatris (VTRS) recorded quarterly Research & Development of $248.6 million in Q1 2026, down 9.5% quarter-over-quarter from $274.7 million in Q4 2025, and up 11.98% on a YoY basis from $222.0 million in Q1 2025.
Viatris (VTRS) Research & Development (2020 - 2026) Analysis & Trends
Viatris' Research & Development history runs 7 years deep, the most recent figure standing at $248.6 million for Q1 2026.
- In Q1 2026, Research & Development rose 11.98% year-over-year to $248.6 million; the TTM figure through Mar 2026 stood at $992.5 million (up 19.43% YoY), while the FY2025 annual figure was $965.9 million, up 19.44% from the prior year.
- Research & Development was $248.6 million for Q1 2026 at Viatris, down from $274.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $274.7 million in Q4 2025 to a low of $142.3 million in Q1 2022.
- Historically, Research & Development has averaged $205.3 million across 5 years, with a median of $204.1 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Research & Development dropped 22.71% in 2022, then jumped 33.03% in 2025.
- A 5-year view of Research & Development shows it stood at $182.4 million in 2022, then rose by 11.18% to $202.8 million in 2023, then climbed by 1.82% to $206.5 million in 2024, then surged by 33.03% to $274.7 million in 2025, then slipped by 9.5% to $248.6 million in 2026.
- The last three Research & Development figures came in at $248.6 million (Q1 2026), $274.7 million (Q4 2025), and $250.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 222.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 180.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 138.20 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 934,363.43 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 296.20 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 97.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 103.35 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 39.38 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 46.94 Mn |
| 10 | Viatris | - | - | 1.16 Bn | 248.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 248.60 Mn |
| Dec 31, 2025 | 274.70 Mn |
| Sep 30, 2025 | 250.40 Mn |
| Jun 30, 2025 | 218.80 Mn |
| Mar 31, 2025 | 222.00 Mn |
| Dec 31, 2024 | 206.50 Mn |
| Sep 30, 2024 | 198.40 Mn |
| Jun 30, 2024 | 204.10 Mn |
| Mar 31, 2024 | 199.70 Mn |
| Dec 31, 2023 | 202.80 Mn |
| Sep 30, 2023 | 211.20 Mn |
| Jun 30, 2023 | 208.30 Mn |
| Mar 31, 2023 | 182.90 Mn |
| Dec 31, 2022 | 182.40 Mn |
| Sep 30, 2022 | 174.90 Mn |
| Jun 30, 2022 | 162.60 Mn |
| Mar 31, 2022 | 142.30 Mn |
| Dec 31, 2021 | 197.10 Mn |
| Sep 30, 2021 | 152.10 Mn |
| Jun 30, 2021 | 147.70 Mn |